Buckingham Research downgrades Endo Pharmaceuticals (Nasdaq: ENDP) to Neutral.

Buckingham analyst says, "We lower our rating to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE